University of Maryland, School of Medicine, Baltimore, Maryland.
J Am Coll Cardiol. 2013 Sep 24;62(13):1177-83. doi: 10.1016/j.jacc.2013.04.073. Epub 2013 Jun 7.
This study sought to determine if nesiritide increases diuresis in congestive heart failure patients.
In the ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure), 7,141 patients hospitalized with acute decompensated heart failure (ADHF) were randomized to receive nesiritide or placebo for 24 to 168 h, in addition to standard care. There were minimal effects of nesiritide on survival, future hospitalizations, and symptoms. However, whether or not nesiritide increases diuresis in ADHF patients is unknown.
Urine output was measured in 5,864 subjects; of these, 5,320 received loop diuretics and had dose data recorded. Loop diuretics other than furosemide were converted to furosemide equivalent doses. A total of 4,881 patients had complete data. We used logistic regression models to identify the impact of nesiritide on urine output and the factors associated with high urine output.
Median (25th, 75th percentiles) 24-h urine output was 2,280 (1,550, 3,280) ml with nesiritide and 2,200 (1,550, 3,200) ml with placebo (p = NS). Loop diuretic dose (furosemide equivalent) was 80 (40, 140) mg with both nesiritide and placebo. Diuretic dose was a strong predictor of urine output. Other independent predictors included: male sex, greater body mass index, higher diastolic blood pressure, elevated jugular venous pressure, recent weight gain, and lower blood urea nitrogen. The addition of nesiritide did not change urine output. None of the interaction terms between nesiritide and predictors affected the urine output prediction.
Nesiritide did not increase urine output in patients with ADHF. Higher diuretic dose was a strong predictor of higher urine output, but neurohormonal activation (as evidenced by blood urea nitrogen concentration) and lower blood pressure limited diuresis.
本研究旨在确定奈西立肽是否会增加充血性心力衰竭患者的尿量。
在 ASCEND-HF(奈西立肽与失代偿性心力衰竭的急性临床疗效研究)中,7141 名因急性失代偿性心力衰竭(ADHF)住院的患者被随机分为奈西立肽组或安慰剂组,接受 24 至 168 小时的治疗,此外还接受标准治疗。奈西立肽对生存率、未来住院率和症状几乎没有影响。然而,奈西立肽是否会增加 ADHF 患者的尿量尚不清楚。
对 5864 名受试者的尿量进行了测量;其中,5320 名受试者接受了袢利尿剂治疗,并记录了剂量数据。除呋塞米以外的袢利尿剂均转换为呋塞米等效剂量。共有 4881 名患者具有完整的数据。我们使用逻辑回归模型来确定奈西立肽对尿量的影响以及与高尿量相关的因素。
中位数(25 分位数,75 分位数)奈西立肽组 24 小时尿量为 2280(1550,3280)ml,安慰剂组为 2200(1550,3200)ml(p=NS)。奈西立肽组和安慰剂组的袢利尿剂剂量(呋塞米等效剂量)均为 80(40,140)mg。利尿剂剂量是尿量的强有力预测因子。其他独立预测因子包括:男性、更大的体重指数、更高的舒张压、升高的颈静脉压、近期体重增加和更低的血尿素氮。加用奈西立肽并未改变尿量。奈西立肽与预测因子之间的任何交互项均未影响尿量预测。
奈西立肽并未增加 ADHF 患者的尿量。更高的利尿剂剂量是更高尿量的强有力预测因子,但神经激素激活(如血尿素氮浓度所示)和更低的血压限制了利尿作用。